FDA Clears Sarepta for ELEVIDYS Resumption in Ambulatory Duchenne Patients
The US Food and Drug Administration (FDA) has informed Sarepta Therapeutics that it recommends resuming shipments of its gene therapy, ELEVIDYS, to ambulatory patients with Duchenne muscular dystrophy. The decision follows a comprehensive review of available safety information by the FDA. Sarepta will resume shipping ELEVIDYS to sites of care for treatment of ambulatory patients … Read more